Roche Holding AG (MEX:ROP1N) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ROP1N Roche Holding AG MEX:ROP1N
72 GF Score
Price MXN7,698.71
GF Value MXN5,610.66
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

MEX:ROP1N
72GF Score
Roche Holding AG MEX:ROP1N
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (MEX:ROP1N) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of MXN7,698.71 is trading 37.2% above its estimated GF Value™ of MXN5,610.66. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for MEX:ROP1N:

  • Dividends Received:
  • GF Value™: MXN5,610.66 vs. price of MXN7,698.71 (37.2% above fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the MEX:ROP1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
72GF Score

Get the complete analysis for MEX:ROP1N

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN7,698.71
Price
MXN5,610.66
GF Value